ATE543913T1 - Prognostische genexpressionssignatur für patienten mit nichtkleinzelligem lungenkrebs - Google Patents

Prognostische genexpressionssignatur für patienten mit nichtkleinzelligem lungenkrebs

Info

Publication number
ATE543913T1
ATE543913T1 AT08766765T AT08766765T ATE543913T1 AT E543913 T1 ATE543913 T1 AT E543913T1 AT 08766765 T AT08766765 T AT 08766765T AT 08766765 T AT08766765 T AT 08766765T AT E543913 T1 ATE543913 T1 AT E543913T1
Authority
AT
Austria
Prior art keywords
small cell
lung cancer
cell lung
patients
gene expression
Prior art date
Application number
AT08766765T
Other languages
English (en)
Inventor
Paul Roepman
Zandwijk Nico Van
Annuska Maria Glas
Original Assignee
Agendia B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agendia B V filed Critical Agendia B V
Application granted granted Critical
Publication of ATE543913T1 publication Critical patent/ATE543913T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT08766765T 2007-06-01 2008-06-02 Prognostische genexpressionssignatur für patienten mit nichtkleinzelligem lungenkrebs ATE543913T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109466 2007-06-01
PCT/NL2008/050342 WO2008147205A1 (en) 2007-06-01 2008-06-02 Prognostic gene expression signature for non small cell lung cancer patients

Publications (1)

Publication Number Publication Date
ATE543913T1 true ATE543913T1 (de) 2012-02-15

Family

ID=38565783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08766765T ATE543913T1 (de) 2007-06-01 2008-06-02 Prognostische genexpressionssignatur für patienten mit nichtkleinzelligem lungenkrebs

Country Status (6)

Country Link
US (1) US8969000B2 (de)
EP (1) EP2171084B1 (de)
JP (1) JP2010528602A (de)
AT (1) ATE543913T1 (de)
CA (1) CA2689714A1 (de)
WO (1) WO2008147205A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4782854B2 (ja) * 2009-03-10 2011-09-28 ナショナル ヤン−ミン ユニバーシティ 癌患者の潜在的転移能、予後、又は全生存を予測する方法
EP2910648A1 (de) 2009-08-24 2015-08-26 National University Corporation Kanazawa University Nachweis von Gallenwegkrebs durch Genexpressionsprofilierung
CN103562409B (zh) * 2011-05-25 2016-04-27 诺华股份有限公司 肺癌的生物标志物
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
ES2411833B1 (es) * 2011-12-30 2014-07-15 Fundación Para La Investigación Biomédica Del Hospital Clínico San Carlos Método de pronóstico del carcinoma no microcítico de pulmón de estadio I o II.
ES2420079B1 (es) * 2012-02-17 2014-07-22 Fundación Para La Investigación Biomédica Del Hospital Clínico San Carlos Método de clasificación del carcinoma no microcítico de pulmón basado en la identificación de una respuesta inmune intratumoral.
WO2013098457A1 (es) * 2011-12-30 2013-07-04 Fundación Para La Investigación Biomédica Del Hospital Clínico San Carlos Método de clasificación del carcinoma no microcítico de pulmón basado en la identificación de una respuesta inmune intratumoral
WO2015091225A1 (en) * 2013-12-16 2015-06-25 Philip Morris Products S.A. Systems and methods for predicting a smoking status of an individual
CN106442990B (zh) * 2015-08-06 2018-07-27 中国人民解放军军事医学科学院生物医学分析中心 用于预测肺鳞癌患者预后的***
CN111893189B (zh) * 2020-08-24 2021-06-29 秦皇岛市第一医院 检测肺癌相关基因甲基化在制备检测肺癌试剂盒中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236507A1 (en) * 2000-11-29 2002-06-11 Cangen International Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
JP5192632B2 (ja) 2003-12-12 2013-05-08 愛知県 肺癌組織中の遺伝子発現強度を識別する方法
US20050272061A1 (en) * 2004-02-19 2005-12-08 Seattle Genetics, Inc. Expression profiling in non-small cell lung cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DK2402758T3 (da) * 2005-09-19 2014-11-03 Janssen Diagnostics Llc Fremgangsmåder og anvendelser til identificering af oprindelsen af et karcinom med ukendt primær oprindelse

Also Published As

Publication number Publication date
US8969000B2 (en) 2015-03-03
JP2010528602A (ja) 2010-08-26
EP2171084B1 (de) 2012-02-01
CA2689714A1 (en) 2008-12-04
US20100184052A1 (en) 2010-07-22
WO2008147205A1 (en) 2008-12-04
EP2171084A1 (de) 2010-04-07

Similar Documents

Publication Publication Date Title
ATE543913T1 (de) Prognostische genexpressionssignatur für patienten mit nichtkleinzelligem lungenkrebs
Bruning et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1α activity during prolonged hypoxia
He et al. linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer
Wu et al. MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2
Hess et al. MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma
Muralidhar et al. The miR-200 family: versatile players in epithelial ovarian cancer
Zhou et al. Large-scale screens of miRNA-mRNA interactions unveiled that the 3′ UTR of a gene is targeted by multiple miRNAs
WO2007103541A3 (en) Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2014009535A3 (en) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
NO20083461L (no) Genekspresjonsmarkorer for kolorektal cancer-prognose
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2013166186A8 (en) Method for determining complete response to anticancer therapy
NZ596054A (en) Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
WO2012175562A3 (en) Methylation and microrna markers of early-stage non-small cell lung cancer
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
EA201171131A1 (ru) Усовершенствованное определение экспрессии генов
Jiang et al. miRNA expression profiles associated with diagnosis and prognosis in lung cancer
MX347555B (es) Un metodo para analizar una muestra de sangre de un sujeto por la presencia de un marcador de enfermedad.
MX351242B (es) Un metodo para analizar una muestra de sangre de un sujeto por la presencia de un marcador de enfermedad.
Xu et al. A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population
NZ629538A (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
EP2619587A4 (de) Biomarker zur vorhersage des wiederauftretens eines kolorektalkarzinoms
Hu et al. Downregulation of lncRNA NCK1-AS1 inhibits cancer cell migration and invasion in nasopharyngeal carcinoma by upregulating miR-135a
de Melo Maia et al. Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma
WO2015091575A3 (en) Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer